hydroxychloroquine has been researched along with Disease Models, Animal in 49 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Hydroxychloroquine, an original antimalarial drug, prevents inflammation caused by lupus erythematosus and rheumatoid arthritis." | 7.83 | Hydroxychloroquine, a promising choice for coronary artery disease? ( Bai, X; Li, R; Liu, J; Liu, M; Ma, Q; Sun, L; Wei, Y; Wu, Y; Yang, Y; Yuan, Z; Zhang, L; Zhao, Q; Zhou, J, 2016) |
| "It has been shown that following demyelination, Oligodendrocyte Progenitor Cells (OPCs) migrate to the lesion site and begin to proliferate, and differentiate." | 5.62 | Analysis of platelet-derived growth factor receptor A and oligodendrocyte transcription factor 2 markers following Hydroxychloroquine administration in animal induced multiple sclerosis model. ( Aliomrani, M; Eftekhari, SM; Safaei, HA, 2021) |
| "Moreover, the effects of HCQ treatment for rosacea patients were investigated." | 5.56 | Hydroxychloroquine is a novel therapeutic approach for rosacea. ( Deng, Z; Huang, Y; Li, J; Liu, F; Tang, Y; Wang, B; Yuan, X; Zhang, Y; Zhao, Z, 2020) |
| "Thrombosis was assessed both in vitro by measuring thrombin generation time (TGT) and tissue factor (TF) expression and in vivo by the measurement of the time to occlusion in carotid and the total thrombosis area in mesenteric arteries." | 5.51 | Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction. ( Benhamou, Y; Billoir, P; Damian, L; Galas, L; Joannides, R; Jouen, F; Le Besnerais, M; Le Cam-Duchez, V; Levesque, H; Miranda, S; Richard, V; Schapman, D; Thiebaut, PA, 2019) |
| "Antiphospholipid syndrome is associated with endothelial dysfunction, which leads to thrombosis and early atheroma." | 5.48 | Hydroxychloroquine partially prevents endothelial dysfunction induced by anti-beta-2-GPI antibodies in an in vivo mouse model of antiphospholipid syndrome. ( Begorre, MA; Belizna, C; Caillon, A; Henrion, D; Kauffenstein, G; Loufrani, L; Poli, C; Urbanski, G, 2018) |
| " Hydroxychloroquine prevented atherosclerosis progression mainly by reversing immune status abnormality caused by SLE." | 3.96 | Systemic lupus erythematosus aggravates atherosclerosis by promoting IgG deposition and inflammatory cell imbalance. ( Duan, XW; Liu, T; Niu, H; Shi, N; Silverman, GJ; Zhang, S, 2020) |
| " Hydroxychloroquine, an original antimalarial drug, prevents inflammation caused by lupus erythematosus and rheumatoid arthritis." | 3.83 | Hydroxychloroquine, a promising choice for coronary artery disease? ( Bai, X; Li, R; Liu, J; Liu, M; Ma, Q; Sun, L; Wei, Y; Wu, Y; Yang, Y; Yuan, Z; Zhang, L; Zhao, Q; Zhou, J, 2016) |
| "The purpose of this study was to investigate the propensity of hydroxychloroquine (HCQ) to cause bradycardia." | 3.81 | Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential. ( Bub, G; Burton, RA; Capel, RA; Channon, K; Douglas, G; Herring, N; Kalla, M; Mirams, GR; Paterson, DJ; Terrar, DA; Yavari, A, 2015) |
| "The aim of this study was to determine if Rituximab coated Biodegradable Nanoparticles (BNPs) loaded with Chlorambucil and Hydroxychloroquine could induce apoptosis of B-Chronic Lymphocytic Leukemia (B-CLL), MEC-1 and BJAB cells in vitro and evaluate their toxic and therapeutic effects on a Human/Mouse Model of Burkitt Lymphoma at an exploratory, proof of concept scale." | 3.76 | Exploratory study on the effects of biodegradable nanoparticles with drugs on malignant B cells and on a human/mouse model of Burkitt lymphoma. ( Ingrao, S; Larsen, G; Maceira, A; Macor, P; Mansilla, E; Marín, GH; Mertz, C; Mezzaroba, N; Núñez, L; Spretz, R; Tau, JM; Tedesco, F; Tripodo, C; Zorzet, S, 2010) |
| "Hydroxychloroquine (HCQ) has already been used clinically for decades, and it is still widely used to treat various autoimmune diseases." | 3.11 | Hydroxychloroquine attenuates neuroinflammation following traumatic brain injury by regulating the TLR4/NF-κB signaling pathway. ( Chen, K; Chen, X; Fang, Y; Guo, K; Hu, J; Liang, F; Lin, L; Peng, W; Tan, X; Wang, X; Wang, Z; Xiong, Y, 2022) |
| "As hydroxychloroquine (HCQ) has recently been shown to inactivate STAT3, we hypothesized that it may impact AD pathogenesis and risk." | 1.91 | Hydroxychloroquine lowers Alzheimer's disease and related dementias risk and rescues molecular phenotypes related to Alzheimer's disease. ( Anerillas, C; Chin, K; Desai, RJ; Gerhard, T; Gorospe, M; Horton, DB; Kim, SC; Loeffler, T; Mahesri, M; Navakkode, S; Sajikumar, S; Schilcher, I; Schneeweiss, S; Segal, JB; Thambisetty, M; Varma, VR; Wong, LW, 2023) |
| "Hydroxychloroquine was observed to promote the self-renewal of club cells and differentiation of ciliated and goblet cells in vitro." | 1.72 | Organoid technology and lung injury mouse models evaluating effects of hydroxychloroquine on lung epithelial regeneration. ( Chen, H; Hou, Z; Li, X; Wang, J; Wang, Q; Wu, Q; Zhang, Y; Zhao, F, 2022) |
| "It has been shown that following demyelination, Oligodendrocyte Progenitor Cells (OPCs) migrate to the lesion site and begin to proliferate, and differentiate." | 1.62 | Analysis of platelet-derived growth factor receptor A and oligodendrocyte transcription factor 2 markers following Hydroxychloroquine administration in animal induced multiple sclerosis model. ( Aliomrani, M; Eftekhari, SM; Safaei, HA, 2021) |
| "Ursodeoxycholic acid (UDCA) has been widely used in the treatment of primary biliary cholangitis (PBC) with chronic liver fibrosis, but its detailed mechanism remains unclear." | 1.56 | Ursodeoxycholic acid alleviates experimental liver fibrosis involving inhibition of autophagy. ( Chen, L; Chen, XZ; Wu, PB; Ye, HL; Zhang, G; Zhang, JW, 2020) |
| "Moreover, the effects of HCQ treatment for rosacea patients were investigated." | 1.56 | Hydroxychloroquine is a novel therapeutic approach for rosacea. ( Deng, Z; Huang, Y; Li, J; Liu, F; Tang, Y; Wang, B; Yuan, X; Zhang, Y; Zhao, Z, 2020) |
| "Thrombosis was assessed both in vitro by measuring thrombin generation time (TGT) and tissue factor (TF) expression and in vivo by the measurement of the time to occlusion in carotid and the total thrombosis area in mesenteric arteries." | 1.51 | Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction. ( Benhamou, Y; Billoir, P; Damian, L; Galas, L; Joannides, R; Jouen, F; Le Besnerais, M; Le Cam-Duchez, V; Levesque, H; Miranda, S; Richard, V; Schapman, D; Thiebaut, PA, 2019) |
| "Hepatic cysts arise from cholangiocytes exhibiting a hyperproliferative phenotype." | 1.48 | Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target. ( Ding, JF; Huang, BQ; LaRusso, NF; Loarca, L; Lorenzo Pisarello, MJ; Masyuk, AI; Masyuk, TV, 2018) |
| "Antiphospholipid syndrome is associated with endothelial dysfunction, which leads to thrombosis and early atheroma." | 1.48 | Hydroxychloroquine partially prevents endothelial dysfunction induced by anti-beta-2-GPI antibodies in an in vivo mouse model of antiphospholipid syndrome. ( Begorre, MA; Belizna, C; Caillon, A; Henrion, D; Kauffenstein, G; Loufrani, L; Poli, C; Urbanski, G, 2018) |
| "Hydroxychloroquine (HCQ) has been used for decades to treat patients with rheumatic diseases, for example, systemic lupus erythematosus (SLE), rheumatoid arthritis or the antiphospholipid syndrome (APS)." | 1.46 | Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase. ( Canisius, A; Lackner, KJ; Manukyan, D; Müller-Calleja, N; Strand, D, 2017) |
| "Hydroxychloroquine-treated lupus patients showed a lower incidence of thromboembolic disease." | 1.40 | Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus. ( Algieri, F; Duarte, J; Gálvez, J; Gómez-Guzmán, M; Gómez-Morales, M; Jiménez, R; López-Farré, AJ; O'Valle, F; Pérez-Vizcaino, F; Romero, M; Sabio, JM; Sánchez, M; Zarzuelo, MJ, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.04) | 29.6817 |
| 2010's | 25 (51.02) | 24.3611 |
| 2020's | 23 (46.94) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 2 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Cochin, M | 1 |
| Touret, F | 2 |
| Driouich, JS | 1 |
| Moureau, G | 1 |
| Petit, PR | 1 |
| Laprie, C | 1 |
| Solas, C | 3 |
| de Lamballerie, X | 2 |
| Nougairède, A | 1 |
| Homme, RP | 1 |
| George, AK | 1 |
| Singh, M | 1 |
| Smolenkova, I | 1 |
| Zheng, Y | 1 |
| Pushpakumar, S | 1 |
| Tyagi, SC | 1 |
| Zhao, F | 1 |
| Wang, J | 1 |
| Wang, Q | 1 |
| Hou, Z | 1 |
| Zhang, Y | 2 |
| Li, X | 1 |
| Wu, Q | 2 |
| Chen, H | 3 |
| Hu, J | 1 |
| Wang, X | 1 |
| Chen, X | 1 |
| Fang, Y | 1 |
| Chen, K | 1 |
| Peng, W | 1 |
| Wang, Z | 2 |
| Guo, K | 1 |
| Tan, X | 1 |
| Liang, F | 1 |
| Lin, L | 1 |
| Xiong, Y | 1 |
| Zeng, P | 1 |
| Jiang, Z | 1 |
| Huang, Z | 1 |
| Huang, Y | 2 |
| Xu, H | 1 |
| Chen, C | 2 |
| Ma, W | 1 |
| Varma, VR | 1 |
| Desai, RJ | 1 |
| Navakkode, S | 1 |
| Wong, LW | 1 |
| Anerillas, C | 1 |
| Loeffler, T | 1 |
| Schilcher, I | 1 |
| Mahesri, M | 1 |
| Chin, K | 1 |
| Horton, DB | 1 |
| Kim, SC | 1 |
| Gerhard, T | 1 |
| Segal, JB | 1 |
| Schneeweiss, S | 1 |
| Gorospe, M | 1 |
| Sajikumar, S | 1 |
| Thambisetty, M | 1 |
| Ye, HL | 1 |
| Zhang, JW | 1 |
| Chen, XZ | 1 |
| Wu, PB | 1 |
| Chen, L | 1 |
| Zhang, G | 1 |
| Li, J | 2 |
| Yuan, X | 1 |
| Tang, Y | 1 |
| Wang, B | 2 |
| Deng, Z | 1 |
| Liu, F | 1 |
| Zhao, Z | 1 |
| Liu, T | 2 |
| Shi, N | 1 |
| Zhang, S | 3 |
| Silverman, GJ | 1 |
| Duan, XW | 1 |
| Niu, H | 1 |
| Mansour, MA | 1 |
| Ibrahim, WM | 1 |
| Salama, MM | 1 |
| Salama, AF | 1 |
| Zhang, Q | 1 |
| Wang, F | 1 |
| Guo, X | 1 |
| Zhao, Y | 1 |
| Gu, B | 1 |
| Li, Y | 1 |
| Park, SJ | 1 |
| Yu, KM | 1 |
| Kim, YI | 1 |
| Kim, SM | 1 |
| Kim, EH | 1 |
| Kim, SG | 1 |
| Kim, EJ | 1 |
| Casel, MAB | 1 |
| Rollon, R | 1 |
| Jang, SG | 1 |
| Chang, JH | 1 |
| Song, MS | 1 |
| Jeong, HW | 1 |
| Choi, Y | 1 |
| Chen, W | 1 |
| Shin, WJ | 1 |
| Jung, JU | 1 |
| Choi, YK | 1 |
| Maisonnasse, P | 1 |
| Guedj, J | 1 |
| Contreras, V | 1 |
| Behillil, S | 1 |
| Marlin, R | 1 |
| Naninck, T | 1 |
| Pizzorno, A | 1 |
| Lemaitre, J | 1 |
| Gonçalves, A | 1 |
| Kahlaoui, N | 1 |
| Terrier, O | 1 |
| Fang, RHT | 1 |
| Enouf, V | 1 |
| Dereuddre-Bosquet, N | 1 |
| Brisebarre, A | 1 |
| Chapon, C | 1 |
| Hoen, B | 1 |
| Lina, B | 1 |
| Calatrava, MR | 1 |
| van der Werf, S | 1 |
| Le Grand, R | 1 |
| Ji, Y | 1 |
| Liu, X | 1 |
| Xie, X | 1 |
| Huang, M | 1 |
| Jiang, J | 1 |
| Liao, YP | 1 |
| Donahue, T | 1 |
| Meng, H | 1 |
| Li, C | 1 |
| Cheng, G | 1 |
| Liu, P | 1 |
| Zhao, L | 1 |
| Ferrere, G | 1 |
| Alves-Costa-Silva, C | 1 |
| Ly, P | 1 |
| Tian, AL | 1 |
| Derosa, L | 1 |
| Zitvogel, L | 1 |
| Kepp, O | 1 |
| Kroemer, G | 1 |
| Zuchelkowski, BE | 1 |
| Wang, L | 1 |
| Gingras, S | 1 |
| Xu, Q | 1 |
| Yang, M | 1 |
| Triulzi, D | 1 |
| Page, GP | 1 |
| Gordeuk, VR | 1 |
| Kim-Shapiro, DB | 1 |
| Lee, JS | 1 |
| Gladwin, MT | 1 |
| Kaptein, SJF | 1 |
| Jacobs, S | 1 |
| Langendries, L | 1 |
| Seldeslachts, L | 1 |
| Ter Horst, S | 1 |
| Liesenborghs, L | 1 |
| Hens, B | 1 |
| Vergote, V | 1 |
| Heylen, E | 1 |
| Barthelemy, K | 1 |
| Maas, E | 1 |
| De Keyzer, C | 1 |
| Bervoets, L | 1 |
| Rymenants, J | 1 |
| Van Buyten, T | 1 |
| Zhang, X | 1 |
| Abdelnabi, R | 1 |
| Pang, J | 1 |
| Williams, R | 1 |
| Thibaut, HJ | 1 |
| Dallmeier, K | 1 |
| Boudewijns, R | 1 |
| Wouters, J | 1 |
| Augustijns, P | 1 |
| Verougstraete, N | 1 |
| Cawthorne, C | 1 |
| Breuer, J | 1 |
| Weynand, B | 1 |
| Annaert, P | 1 |
| Spriet, I | 1 |
| Vande Velde, G | 1 |
| Neyts, J | 1 |
| Rocha-Pereira, J | 1 |
| Delang, L | 1 |
| Rosenke, K | 1 |
| Jarvis, MA | 1 |
| Feldmann, F | 1 |
| Schwarz, B | 1 |
| Okumura, A | 1 |
| Lovaglio, J | 1 |
| Saturday, G | 1 |
| Hanley, PW | 1 |
| Meade-White, K | 1 |
| Williamson, BN | 1 |
| Hansen, F | 1 |
| Perez-Perez, L | 1 |
| Leventhal, S | 1 |
| Tang-Huau, TL | 1 |
| Callison, J | 1 |
| Haddock, E | 1 |
| Stromberg, KA | 1 |
| Scott, D | 1 |
| Sewell, G | 1 |
| Bosio, CM | 1 |
| Hawman, D | 1 |
| de Wit, E | 1 |
| Feldmann, H | 1 |
| Brown, D | 1 |
| Moezzi, D | 1 |
| Dong, Y | 1 |
| Koch, M | 2 |
| Yong, VW | 2 |
| Chen, Y | 1 |
| Li, MX | 1 |
| Lu, GD | 1 |
| Shen, HM | 1 |
| Zhou, J | 2 |
| Safaei, HA | 1 |
| Eftekhari, SM | 1 |
| Aliomrani, M | 1 |
| Faissner, S | 1 |
| Mahjoub, Y | 1 |
| Mishra, M | 1 |
| Haupeltshofer, S | 1 |
| Hahn, JN | 1 |
| Gold, R | 1 |
| Metz, LM | 1 |
| Ben-Hur, T | 1 |
| Liu, L | 1 |
| Ren, J | 1 |
| He, Z | 1 |
| Men, K | 1 |
| Mao, Y | 1 |
| Ye, T | 1 |
| Li, L | 1 |
| Xu, B | 1 |
| Wei, Y | 2 |
| Wei, X | 1 |
| Masyuk, AI | 1 |
| Masyuk, TV | 1 |
| Lorenzo Pisarello, MJ | 1 |
| Ding, JF | 1 |
| Loarca, L | 1 |
| Huang, BQ | 1 |
| LaRusso, NF | 1 |
| Cao, B | 1 |
| Sheth, MN | 1 |
| Mysorekar, IU | 1 |
| Tang, TT | 1 |
| Lv, LL | 1 |
| Pan, MM | 1 |
| Wen, Y | 1 |
| Li, ZL | 1 |
| Wu, M | 1 |
| Wang, FM | 1 |
| Crowley, SD | 1 |
| Liu, BC | 1 |
| Fang, L | 1 |
| Song, HH | 1 |
| Zhou, YF | 1 |
| Yan, YP | 1 |
| Qiu, W | 1 |
| Urbanski, G | 1 |
| Caillon, A | 1 |
| Poli, C | 1 |
| Kauffenstein, G | 1 |
| Begorre, MA | 1 |
| Loufrani, L | 1 |
| Henrion, D | 1 |
| Belizna, C | 1 |
| Hedya, SA | 1 |
| Safar, MM | 1 |
| Bahgat, AK | 1 |
| Miranda, S | 1 |
| Billoir, P | 1 |
| Damian, L | 1 |
| Thiebaut, PA | 1 |
| Schapman, D | 1 |
| Le Besnerais, M | 1 |
| Jouen, F | 1 |
| Galas, L | 1 |
| Levesque, H | 1 |
| Le Cam-Duchez, V | 1 |
| Joannides, R | 1 |
| Richard, V | 1 |
| Benhamou, Y | 1 |
| Dyer, MR | 1 |
| Alexander, W | 1 |
| Hassoune, A | 1 |
| Chen, Q | 1 |
| Brzoska, T | 1 |
| Alvikas, J | 1 |
| Liu, Y | 1 |
| Haldeman, S | 1 |
| Plautz, W | 1 |
| Loughran, P | 1 |
| Li, H | 1 |
| Boone, B | 1 |
| Sadovsky, Y | 1 |
| Sundd, P | 1 |
| Zuckerbraun, BS | 1 |
| Neal, MD | 1 |
| Mezzaroba, N | 2 |
| Zorzet, S | 2 |
| Secco, E | 1 |
| Biffi, S | 1 |
| Tripodo, C | 2 |
| Calvaruso, M | 1 |
| Mendoza-Maldonado, R | 1 |
| Capolla, S | 1 |
| Granzotto, M | 1 |
| Spretz, R | 2 |
| Larsen, G | 2 |
| Noriega, S | 1 |
| Lucafò, M | 1 |
| Mansilla, E | 2 |
| Garrovo, C | 1 |
| Marín, GH | 2 |
| Baj, G | 1 |
| Gattei, V | 1 |
| Pozzato, G | 1 |
| Núñez, L | 2 |
| Macor, P | 2 |
| Rosenfeldt, MT | 1 |
| O'Prey, J | 1 |
| Morton, JP | 1 |
| Nixon, C | 1 |
| MacKay, G | 1 |
| Mrowinska, A | 1 |
| Au, A | 1 |
| Rai, TS | 1 |
| Zheng, L | 1 |
| Ridgway, R | 1 |
| Adams, PD | 1 |
| Anderson, KI | 1 |
| Gottlieb, E | 1 |
| Sansom, OJ | 1 |
| Ryan, KM | 1 |
| Gómez-Guzmán, M | 1 |
| Jiménez, R | 1 |
| Romero, M | 1 |
| Sánchez, M | 1 |
| Zarzuelo, MJ | 1 |
| Gómez-Morales, M | 1 |
| O'Valle, F | 1 |
| López-Farré, AJ | 1 |
| Algieri, F | 1 |
| Gálvez, J | 1 |
| Pérez-Vizcaino, F | 1 |
| Sabio, JM | 1 |
| Duarte, J | 1 |
| Poklepovic, A | 1 |
| Gewirtz, DA | 1 |
| Yang, A | 1 |
| Kimmelman, AC | 1 |
| Capel, RA | 1 |
| Herring, N | 1 |
| Kalla, M | 1 |
| Yavari, A | 1 |
| Mirams, GR | 1 |
| Douglas, G | 1 |
| Bub, G | 1 |
| Channon, K | 1 |
| Paterson, DJ | 1 |
| Terrar, DA | 1 |
| Burton, RA | 1 |
| Li, CL | 2 |
| He, J | 2 |
| Li, ZG | 2 |
| Zheng, LW | 2 |
| Hua, H | 2 |
| Virdis, A | 1 |
| Tani, C | 1 |
| Duranti, E | 1 |
| Vagnani, S | 1 |
| Carli, L | 1 |
| Kühl, AA | 1 |
| Solini, A | 1 |
| Baldini, C | 1 |
| Talarico, R | 1 |
| Bombardieri, S | 1 |
| Taddei, S | 1 |
| Mosca, M | 1 |
| Ruiz, A | 1 |
| Rockfield, S | 1 |
| Taran, N | 1 |
| Haller, E | 1 |
| Engelman, RW | 1 |
| Flores, I | 1 |
| Panina-Bordignon, P | 1 |
| Nanjundan, M | 1 |
| Andrade, D | 1 |
| Tektonidou, M | 1 |
| Sun, L | 1 |
| Liu, M | 1 |
| Li, R | 1 |
| Zhao, Q | 1 |
| Liu, J | 1 |
| Yang, Y | 1 |
| Zhang, L | 1 |
| Bai, X | 1 |
| Ma, Q | 1 |
| Yuan, Z | 1 |
| Wu, Y | 1 |
| Müller-Calleja, N | 1 |
| Manukyan, D | 1 |
| Canisius, A | 1 |
| Strand, D | 1 |
| Lackner, KJ | 1 |
| Tau, JM | 1 |
| Maceira, A | 1 |
| Mertz, C | 1 |
| Ingrao, S | 1 |
| Tedesco, F | 1 |
| Garber, K | 1 |
| Wang, Y | 1 |
| Yan, T | 1 |
| Shen, J | 1 |
| Guo, H | 1 |
| Xiang, X | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Silver Nanoparticles as an Oropharyngeal Product (Mouthwash) and Nasal Hygiene, by Health Personnel Working at the Tijuana General Hospital Exposed to Patients Diagnosed With Atypical Pneumonia Caused by SARS-CoV-2[NCT04894409] | 231 participants (Actual) | Interventional | 2020-04-24 | Completed | |||
| Efficacy and Safety of the Use of Hydroxychloroquine, Favipiravir or Hydroxychloroquine + Favipiravir in Early SARS-CoV-2 (COVID-19) Treatment[NCT04981379] | Phase 3 | 1,120 participants (Actual) | Interventional | 2020-11-16 | Completed | ||
| Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Hydroxychloroquine 200mg BID for Reducing Progression of Disability in Patients With Primary Progressive Multiple Sclerosis (PPMS)[NCT02913157] | Phase 2 | 35 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography.[NCT02874287] | Phase 4 | 35 participants (Actual) | Interventional | 2017-10-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for hydroxychloroquine and Disease Models, Animal
| Article | Year |
|---|---|
Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?
Topics: Animals; Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 | 2020 |
Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: Truth under the Mystery.
Topics: Animals; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Disease Models, Animal; E | 2021 |
Emerging Therapies in Antiphospholipid Syndrome.
Topics: Animals; Anticoagulants; Antiphospholipid Syndrome; Complement Inactivating Agents; Disease Models, | 2016 |
1 trial available for hydroxychloroquine and Disease Models, Animal
| Article | Year |
|---|---|
Hydroxychloroquine attenuates neuroinflammation following traumatic brain injury by regulating the TLR4/NF-κB signaling pathway.
Topics: Animals; Brain Injuries, Traumatic; Disease Models, Animal; Hydroxychloroquine; Mice; Mice, Inbred C | 2022 |
45 other studies available for hydroxychloroquine and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model.
Topics: Animals; Anti-Infective Agents; Azithromycin; Bronchi; Chlorocebus aethiops; COVID-19 Drug Treatment | 2022 |
Mechanism of Blood-Heart-Barrier Leakage: Implications for COVID-19 Induced Cardiovascular Injury.
Topics: Animals; Blood; Blood Physiological Phenomena; Cardiomegaly; Cardiovascular Diseases; Cardiovascular | 2021 |
Organoid technology and lung injury mouse models evaluating effects of hydroxychloroquine on lung epithelial regeneration.
Topics: Animals; Bleomycin; Cell Differentiation; COVID-19 Drug Treatment; Disease Models, Animal; Hydroxych | 2022 |
PI3K/AKT/mTOR Signaling Pathway Is Downregulated by Runzaoling (RZL) in Sjögren's Syndrome.
Topics: Animals; Disease Models, Animal; Down-Regulation; Hydroxychloroquine; Interleukin-17; Mice; Mice, In | 2022 |
Hydroxychloroquine lowers Alzheimer's disease and related dementias risk and rescues molecular phenotypes related to Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Disease Models, A | 2023 |
Ursodeoxycholic acid alleviates experimental liver fibrosis involving inhibition of autophagy.
Topics: Animals; Autophagy; Blotting, Western; Cell Line; Disease Models, Animal; Humans; Hydroxychloroquine | 2020 |
Hydroxychloroquine is a novel therapeutic approach for rosacea.
Topics: Animals; Anti-Inflammatory Agents; Calcium Signaling; Cells, Cultured; Cytokines; Disease Models, An | 2020 |
Systemic lupus erythematosus aggravates atherosclerosis by promoting IgG deposition and inflammatory cell imbalance.
Topics: Animals; Atherosclerosis; Dendritic Cells; Disease Models, Animal; Disease Progression; Female; Hydr | 2020 |
Dual inhibition of glycolysis and autophagy as a therapeutic strategy in the treatment of Ehrlich ascites carcinoma.
Topics: Animals; Antineoplastic Agents; Antioxidants; Autophagy; Carcinoma, Ehrlich Tumor; Cell Proliferatio | 2020 |
Hydroxychloroquine inhibiting neutrophil extracellular trap formation alleviates hepatic ischemia/reperfusion injury by blocking TLR9 in mice.
Topics: Animals; Disease Models, Animal; Extracellular Traps; Hydroxychloroquine; Liver; Male; Mice; Mice, I | 2020 |
Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
Topics: Animals; Antibodies, Neutralizing; Antibodies, Viral; Antiviral Agents; Betacoronavirus; Coronavirus | 2020 |
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.
Topics: Animals; Azithromycin; Betacoronavirus; Chlorocebus aethiops; Coronavirus Infections; COVID-19; COVI | 2020 |
Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment.
Topics: Animals; Apoptosis; Autophagy; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cyclin-Dependent Kina | 2020 |
Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azithromycin; Cell Line, Tumor; Cisplatin; | 2020 |
Brief Report: Hydroxychloroquine does not induce hemolytic anemia or organ damage in a "humanized" G6PD A- mouse model.
Topics: Animals; Black or African American; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Disea | 2020 |
Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.
Topics: Amides; Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Coronavirus Infections; CO | 2020 |
Hydroxychloroquine prophylaxis and treatment is ineffective in macaque and hamster SARS-CoV-2 disease models.
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Cricetinae; Cyto | 2020 |
Combination of Hydroxychloroquine and Indapamide Attenuates Neurodegeneration in Models Relevant to Multiple Sclerosis.
Topics: Animals; Brain; Cells, Cultured; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; | 2021 |
Analysis of platelet-derived growth factor receptor A and oligodendrocyte transcription factor 2 markers following Hydroxychloroquine administration in animal induced multiple sclerosis model.
Topics: Animals; Corpus Callosum; Cuprizone; Demyelinating Diseases; Disease Models, Animal; Hydroxychloroqu | 2021 |
Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?
Topics: Animals; B-Lymphocytes; Cell Proliferation; Disease Models, Animal; Encephalomyelitis, Autoimmune, E | 2018 |
Cholesterol-modified Hydroxychloroquine-loaded Nanocarriers in Bleomycin-induced Pulmonary Fibrosis.
Topics: Animals; Apoptosis; Biomarkers; Bleomycin; Cholesterol; Cytokines; Disease Models, Animal; Drug Carr | 2017 |
Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target.
Topics: Animals; Autophagy; Bile Ducts; Blotting, Western; Cell Proliferation; Cells, Cultured; Cluster Anal | 2018 |
To Zika and destroy: an antimalarial drug protects fetuses from Zika infection.
Topics: Animals; Antimalarials; Autophagy; Disease Models, Animal; Drug Repositioning; Female; Fetus; Humans | 2018 |
Hydroxychloroquine attenuates renal ischemia/reperfusion injury by inhibiting cathepsin mediated NLRP3 inflammasome activation.
Topics: Acute Kidney Injury; Animals; Anti-Inflammatory Agents; Cathepsin B; Cathepsin L; Cell Line; Cell Su | 2018 |
Hydroxychloroquine fails to attenuate lesion development in a mouse model of neuromyelitis optica.
Topics: Animals; Brain; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Enzyme Inhibitors; Female | 2018 |
Hydroxychloroquine partially prevents endothelial dysfunction induced by anti-beta-2-GPI antibodies in an in vivo mouse model of antiphospholipid syndrome.
Topics: Animals; Antibodies, Anti-Idiotypic; Antiphospholipid Syndrome; beta 2-Glycoprotein I; Disease Model | 2018 |
Hydroxychloroquine antiparkinsonian potential: Nurr1 modulation versus autophagy inhibition.
Topics: Animals; Antiparkinson Agents; Apoptosis; Autophagy; Disease Models, Animal; Glycogen Synthase Kinas | 2019 |
Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction.
Topics: Animals; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Disease Models, Animal; Endothelia | 2019 |
Platelet-derived extracellular vesicles released after trauma promote hemostasis and contribute to DVT in mice.
Topics: Adult; Aged; Animals; Blood Platelets; Disease Models, Animal; Extracellular Vesicles; Female; Fibri | 2019 |
New potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Apoptosis; Autophagy; Cell Survival | 2013 |
p53 status determines the role of autophagy in pancreatic tumour development.
Topics: Alleles; Animals; Autophagy; Autophagy-Related Protein 5; Autophagy-Related Protein 7; Carcinoma, Pa | 2013 |
Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus.
Topics: Acute Kidney Injury; Animals; Blood Pressure; Disease Models, Animal; Endothelium, Vascular; Enzyme | 2014 |
Outcome of early clinical trials of the combination of hydroxychloroquine with chemotherapy in cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Clinical | 2014 |
Inhibition of autophagy attenuates pancreatic cancer growth independent of TP53/TRP53 status.
Topics: Animals; Autophagy; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Disease Models, Animal; Humans; | 2014 |
Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential.
Topics: Action Potentials; Animals; Bradycardia; Disease Models, Animal; Electrophysiological Phenomena; Enz | 2015 |
Effects of Multi-glycosides of Tripterygium wilfordiion in the Treatment of Sjögren's Syndrome in the Non-obese Diabetic Mouse Model.
Topics: Animals; Antibodies, Antinuclear; Body Weight; CD4 Lymphocyte Count; Disease Models, Animal; Female; | 2015 |
Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus.
Topics: Animals; Antioxidants; Antirheumatic Agents; Disease Models, Animal; Endothelium, Vascular; Female; | 2015 |
Effect of hydroxychloroquine and characterization of autophagy in a mouse model of endometriosis.
Topics: Animals; Autophagy; Disease Models, Animal; Endometriosis; Female; Humans; Hydroxychloroquine; Mice | 2016 |
Hydroxychloroquine, a promising choice for coronary artery disease?
Topics: Animals; Antimalarials; Arthritis, Rheumatoid; Coronary Artery Disease; Disease Models, Animal; Huma | 2016 |
Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase.
Topics: Adult; Aged; Animals; Antibodies, Antiphospholipid; Antirheumatic Agents; Cells, Cultured; Disease M | 2017 |
Exploratory study on the effects of biodegradable nanoparticles with drugs on malignant B cells and on a human/mouse model of Burkitt lymphoma.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; B-Lymphocytes; Burkitt Lymph | 2010 |
Inducing indigestion: companies embrace autophagy inhibitors.
Topics: Animals; Antimalarials; Antineoplastic Agents; Autophagy; Cell Hypoxia; Cell Survival; Clinical Tria | 2011 |
Effects of total glucosides of paeony for delaying onset of Sjogren's syndrome: an animal study.
Topics: Animals; Autoantigens; Disease Models, Animal; Enzyme Inhibitors; Female; Gene Expression Profiling; | 2013 |
Preventive effect of Ophiopogon japonicus polysaccharides on an autoallergic mouse model for Sjogren's syndrome by regulating the Th1/Th2 cytokine imbalance.
Topics: Animals; Autoantigens; Autoimmune Diseases; Body Weight; Cytokines; Disease Models, Animal; Drinking | 2007 |